We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Entelos Announces U.S. Patent for the Development and Use of Virtual Patients

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Entelos, Inc. has announced that the Patent and Trademark Office has issued U.S. Patent No. 6,983,237, entitled "Method and Apparatus for Conducting Linked Simulation Operations Utilizing a Computer-Based System Model."

This patent was awarded to Entelos for its invention of a key technology to effectively develop and use virtual patients - in silico representations of actual patient subpopulations.

This technology is designed to allow Entelos researchers to rapidly assess the safety and efficacy of drugs for pharmaceutical research and personalized medicine purposes.

"This patent represents yet another milestone in Entelos' intellectual property strategy, and indicates the company's commitment to protecting its leadership position in the field of predictive biosimulation," stated Charles Sholtz, J.D., Ph.D., Vice President, Legal Affairs and Intellectual Property at Entelos.

"Currently, we have 12 issued patents and over 70 pending applications worldwide directed to our software platform; the methodologies of applying our PhysioLab models to pharmaceutical drug discovery and development; and the PhysioLab models themselves."

This patent provides broad coverage for a method to consecutively link biosimulation experiments using a computer model.

The software based on this method allows Entelos scientists to create new virtual patients and effectively use them to validate drug targets, identify biomarkers, translate preclinical data to human outcome, and optimize clinical trial designs.

"By developing this methodology, Entelos can effectively represent patient variability in a computer on both the individual and population scale," stated James Karis, President and CEO of Entelos.

"This ability allows us to address this critical drug development challenge, which is also a key hurdle in fulfilling the promise of personalized medicine."

"This patent further strengthens our leadership position in biosimulation and lays the framework for Entelos to develop the first-ever virtual human."